



University of South Florida, Performance & Physique Enhancement Laboratory – Tampa, Florida

ABSTRACT

Background

Plasma modification (PM) is a surface treatment technique and is currently being investigated for use in biomaterials. The purpose of this study was to explore PM on dry whey protein isolate (WPI) powder and its effects on altering the bioavailability of oral WPI supplementation in humans.

Materials and Methods

10 resistance-trained males (26.6 ± 6.0) years; 181.4 ± 4.0 cm; 88.4 \pm 9.9kg) participated in this randomized, double-blind investigation. In crossover fashion, participants reported to a Quest Diagnostics facility 2 times separated by 7-days. After a baseline blood sample was taken, participants ingested 25g of a WPI powder that was processed with PM technology (Plasma) or standard processed high DH hydrolyzed WPI (Standard). Further samples were taken at 30min, 1hr, 2hrs, 3hrs, and 4hrs postingestion and analyzed for essential amino acids (EAA) concentrations. Time course data were analyzed via a 2-factor [2x6] within-subjects repeated measures ANOVA and total EAA concentrations and EAA area under the curve (AUC) data were analyzed via paired samples t-test.

Results

The repeated measures ANOVA revealed a significant main effect for time for all EAAs (p<0.001) and a treatment x time interaction (p≤0.017) for all EAA's (with the exception of histidine). Baselineadjusted individual plasma-EAA concentrations are summarized in Table 1. With the exception of histidine, PM treated nonhydrolyzed WPI resulted in significantly greater bioavailability as compared to the standard high DH hydrolyzed WPI dietary supplement. There was also a significant difference between the treatments for total EAA, BCAA, and EAA and BCAA area under the curve (table 2), with PM resulting in significantly greater plasma EAA and BCAA concentrations.

Conclusions

In resistance trained males, a plasma modified non-hydrolyzed whey protein isolate dietary supplement is more bioavailable than a standard hydrolyzed whey protein isolate dietary supplement.

Comparison of a Plasma Modified Non-Hydrolyzed Whey Protein Isolate Supplement and a Standard Processed High DH Hydrolyzed Whey Protein **Isolate Supplement on Bioavailability in Resistance-Trained Males**

Bill I. Campbell and Jaymes Longstrom

Plasma modification (PM) is an effective surface treatment technique for many different materials, and there is growing interest in its use on organic materials like protein. To this point, research on the use of PM to promote surface changes of organic materials has focused largely on experiments using aqueous solutions, particularly as they relate to end-use applications in pharmacological development.

The purpose of this study was to explore PM on dry whey protein isolate (WPI) powder and its effects on altering the bioavailability of oral WPI supplementation in humans.



METHODS

10 resistance-trained males $(26.6 \pm 6.0 \text{ years}; 181.4 \pm 4.0 \text{ cm}; 88.4 \pm 9.9 \text{ kg})$ participated in this randomized, double-blind investigation. In crossover fashion, participants reported to a Quest Diagnostics facility 2 times separated by 7-days. After a baseline blood sample was taken, participants ingested 25g of a WPI powder that was processed with PM technology (Plasma) or standard processed high DH hydrolyzed WPI (Standard). Further samples were taken at 30min, 1hr, 2hrs, 3hrs, and 4hrs postingestion and analyzed for essential amino acids (EAA) concentrations. Time course data were analyzed via a 2-factor [2x6] within-subjects repeated measures ANOVA and total EAA concentrations and EAA area under the curve (AUC) data were analyzed via paired samples t-test.

RESULTS

The repeated measures ANOVA revealed a significant main effect for time for all EAAs (p<0.001) and a treatment x time interaction (p \leq 0.017) for all EAA's (with the exception of histidine). Baseline-adjusted individual plasma-EAA concentrations are summarized in Table 1. With the exception of histidine, PM treated non-hydrolyzed WPI resulted in significantly greater bioavailability as compared to the standard high DH hydrolyzed WPI dietary supplement. There was also a significant difference between the treatments for total EAA, BCAA, and EAA and BCAA area under the curve (table 2), with PM resulting in significantly greater plasma EAA and BCAA concentrations.

BACKGROUND

CONCLUSION

In resistance trained males, a plasma modified non-hydrolyzed whey protein isolate dietary supplement is more bioavailable than a standard hydrolyzed whey protein isolate dietary supplement.

Table 1: Baseline Adjusted Plasma EAA Concentrations (µmol/L)

| | Baseline | 30-min | 1hr | 2hr | 3hr | 4hr | Treatment x Time |
|------------------------|----------|--------|--------|-------|-------|-------|---------------------|
| Plasma-Leucine | 0 | 145±68 | 174±54 | 61±33 | 24±22 | 15±22 | |
| Standard-Leucine | 0 | 160±48 | 82±31 | 20±17 | -1±18 | 4±19 | p = 0.001 |
| Plasma-Isoleucine | 0 | 114±51 | 119±41 | 39±28 | 11±14 | 4±19 | n = 0.012 |
| Standard-Isoleucine | 0 | 112±35 | 61±23 | 14±11 | -2±9 | -3±11 | p = 0.012 |
| Plasma-Valine | 0 | 113±60 | 141±57 | 48±37 | 14±22 | -2±26 | m 0.014 |
| Standard-Valine | 0 | 110±45 | 69±32 | 13±17 | -2±25 | -7±22 | p = 0.014 |
| Plasma-Histidine | 0 | 10±10 | 14±9 | 4±5 | -1±8 | 2±15 | n = 0.724 |
| Standard-Histidine | 0 | 14±10 | 11±7 | 2±7 | -1±13 | -1±6 | p = 0.724 |
| Plasma-Threonine | 0 | 83±39 | 95±41 | 49±26 | 30±16 | 24±15 | <i>a</i> 0.012 |
| Standard-Threonine | 0 | 78±25 | 55±19 | 25±16 | 12±14 | 8±15 | p = 0.013 |
| Plasma-Methionine | 0 | 19±9 | 18±8 | 4±4 | 0±2 | -1±2 | n = 0.017 |
| Standard-Methionine | 0 | 17±5 | 9±4 | 1±2 | -1±3 | -2±3 | p = 0.017 |
| Plasma-Phenylalanine | 0 | 13±10 | 13±4 | -3±6 | -11±2 | -9±7 | ··· 0.001 |
| Standard-Phenylalanine | 0 | 16±10 | 1±12 | -7±5 | -9±9 | -7±8 | p = 0.001 |
| Plasma-Tryptophan | 0 | 30±23 | 46±20 | 20±15 | 5±15 | -1±12 | p = 0.003 |
| Standard-Tryptophan | 0 | 33±13 | 27±9 | 15±8 | 3±13 | -2±13 | |
| Plasma-Lysine | 0 | 108±62 | 130±27 | 50±32 | 23±18 | 22±20 | n < 0.001 |
| Standard-Lysine | 0 | 135±46 | 75±18 | 30±12 | 16±13 | 9±21 | p < 0.001 |

Curve Comparisons

| | Total EAA | p-value | AUC | p-value | |
|---------------|-----------------|---------|---------------|---------|--|
| Plasma-EAA | $7,575\pm1,063$ | 0.02 | $1,784\pm521$ | 0.007 | |
| Standard-EAA | 6,932±911 | 0.02 | $1,200\pm246$ | 0.007 | |
| Plasma-BCAA | 3,961±641 | 0.020 | 1,012±333 | 0.009 | |
| Standard-BCAA | 3,543±407 | 0.039 | 634±207 | | |





Table 2. Total EAA, BCAA (µmol/L) and EAA, BCAA Area Under the

PlasmaNutrition